Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
Merck announced a comprehensive access strategy for Alimatravir (MK-8527), an investigational once-monthly oral HIV PrEP currently in Phase 3 development. The company has signed royalty-free voluntary licensing agreements with seven generic manufacturers to supply the drug in 129 low- and middle-income countries upon potential approval.
Key figures
- Drug Name
- Alimatravir (MK-8527)
- Phase Of Trial
- Phase 3
- Licensees
- 7
- Countries covered
- 129
- Doses evaluated mg
- [3,6,12]
- Oral prep users 2023
- 3.5 million
- Phase 2 participants
- 350
- Global hiv cases 2025
- 1.2 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.